Neurocrine Biosciences Unveils New Findings on INGREZZA® vs AUSTEDO XR for Movement Disorders Neurocrine Biosciences has revealed groundbreaking data showcasing how INGREZZA® (valbenazine) exhibits significantly higher VMAT2 target occupancy than AUSTEDO XR. This discovery could enhance treatment options for movement disorders.

Neurocrine Biosciences Unveils New Findings on INGREZZA® vs AUSTEDO XR for Movement Disorders #USA #San_Diego #INGREZZA #Valbenazine #AUSTEDO_XR